Trial Profile
The efficacy and safety of SGLT2 inhibitor for non alcholic fatty liver disease in Japanese patients with type 2 diabetes
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2016
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Glimepiride
- Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 21 Jul 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 28 Jan 2015 New trial record